Cabaletta Bio Statistics
Total Valuation
Cabaletta Bio has a market cap or net worth of $298.34 million. The enterprise value is $191.84 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cabaletta Bio has 111.32 million shares outstanding. The number of shares has increased by 61.34% in one year.
| Current Share Class | 111.32M |
| Shares Outstanding | 111.32M |
| Shares Change (YoY) | +61.34% |
| Shares Change (QoQ) | +2.48% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 54.18% |
| Float | 91.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.40 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.77 |
| Quick Ratio | 2.66 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -85.95 |
Financial Efficiency
Return on equity (ROE) is -126.98% and return on invested capital (ROIC) is -70.11%.
| Return on Equity (ROE) | -126.98% |
| Return on Assets (ROA) | -61.49% |
| Return on Invested Capital (ROIC) | -70.11% |
| Return on Capital Employed (ROCE) | -149.87% |
| Weighted Average Cost of Capital (WACC) | 20.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 156 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.50% in the last 52 weeks. The beta is 3.28, so Cabaletta Bio's price volatility has been higher than the market average.
| Beta (5Y) | 3.28 |
| 52-Week Price Change | +93.50% |
| 50-Day Moving Average | 2.92 |
| 200-Day Moving Average | 2.29 |
| Relative Strength Index (RSI) | 43.04 |
| Average Volume (20 Days) | 1,867,967 |
Short Selling Information
The latest short interest is 19.04 million, so 17.11% of the outstanding shares have been sold short.
| Short Interest | 19.04M |
| Short Previous Month | 18.64M |
| Short % of Shares Out | 17.11% |
| Short % of Float | 20.89% |
| Short Ratio (days to cover) | 7.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.24M |
| Pretax Income | -167.86M |
| Net Income | -167.86M |
| EBITDA | -170.60M |
| EBIT | -172.24M |
| Earnings Per Share (EPS) | -$2.10 |
Full Income StatementBalance Sheet
The company has $133.60 million in cash and $27.10 million in debt, with a net cash position of $106.50 million or $0.96 per share.
| Cash & Cash Equivalents | 133.60M |
| Total Debt | 27.10M |
| Net Cash | 106.50M |
| Net Cash Per Share | $0.96 |
| Equity (Book Value) | 112.05M |
| Book Value Per Share | 1.12 |
| Working Capital | 88.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$131.08 million and capital expenditures -$1.23 million, giving a free cash flow of -$132.31 million.
| Operating Cash Flow | -131.08M |
| Capital Expenditures | -1.23M |
| Depreciation & Amortization | 1.65M |
| Net Borrowing | -6.26M |
| Free Cash Flow | -132.31M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cabaletta Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -61.34% |
| Shareholder Yield | -61.34% |
| Earnings Yield | -56.26% |
| FCF Yield | -44.35% |
Analyst Forecast
The average price target for Cabaletta Bio is $13.43, which is 401.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.43 |
| Price Target Difference | 401.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
